Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Maze Therapeutics, Inc.NASDAQ: MAZE

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) remains negative

Q1 FY2026 EPS (Diluted) was -$0.45, compared with -$0.75 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.75.

Context

  • EPS (Diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 8 analysts of -$2.8 (+8.2%) for the fiscal year ending Dec 2026, a step up from the -4020.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.45+48.3% QoQ
Last fiscal yearDec 2025
-$3.05-4020.3% YoY
LTMMar 2026
-$2.75-4396.9% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.9%+6.8%-33.0 pp
1 year-4020.3%+8.2%+4028.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(3.05) USD
Year-over-year change
-4020.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -4396.9% is the lowest of 8, against a peer median of -10.9%.
MAZE Competitors
EPS (Diluted) for MAZE and competitors
Company Period LTM YoY 3-year CAGR
ARDXArdelyx, Inc.LTM Mar 2026-$0.24 USD-4.8%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$0.58 USD-108.3%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026-$0.71 USD-10.9%—
SEPNSepterna, Inc.LTM Sep 2026-$1.29 USD+14.6%—
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$1.56 USD-43.1%—
IVAInventiva S.A.FY2025-€1.82 EUR+48.6%—
BIOABioAge Labs, Inc.LTM Mar 2026-$2.4 USD-18.2%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$2.75 USD-4396.9%—
Peer median (excluding MAZE) —-10.9%—

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.